Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
Qiaoshuai Lan, Jasper Fuk‐Woo Chan, Wei Xu, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 549-549
Open Access | Times Cited: 16

Showing 16 citing articles:

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 44
FEOpti-ACVP: identification of novel anti-coronavirus peptide sequences based on feature engineering and optimization
Jici Jiang, Hongdi Pei, Jiayu Li, et al.
Briefings in Bioinformatics (2024) Vol. 25, Iss. 2
Open Access | Times Cited: 6
Computational optimization of a pan-coronavirus fusion inhibitory peptide targeting Spike’s heptapeptide repeat region
Peixiang Gao, Shuo Liu, Xiaojing Chi, et al.
Biosafety and Health (2025)
Open Access
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Qiaoshuai Lan, Lijue Wang, Fanke Jiao, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 22
Development of potent pan‐coronavirus fusion inhibitors with a new design strategy
Yuanmei Zhu, Zhongcai Gao, Xiaoli Feng, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 3
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
Katharina S. Schmitz, Daryl Geers, Rory D. de Vries, et al.
mBio (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 16
SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
Yuanmei Zhu, Xiaojing Dong, Nian Liu, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1819-1827
Open Access | Times Cited: 14
AI-Driven Design of Cell-Penetrating Peptides for Therapeutic Biotechnology
Hongru Ma, Xinzhi Zhou, Ziyue Zhang, et al.
International Journal of Peptide Research and Therapeutics (2024) Vol. 30, Iss. 6
Closed Access | Times Cited: 2
Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
Yuanmei Zhu, Yue Hu, Nian Liu, et al.
Antiviral Research (2022) Vol. 208, pp. 105445-105445
Open Access | Times Cited: 12
Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives
Toni Todorovski, Daniela Kalafatović, David Andreu
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 357-357
Open Access | Times Cited: 6
An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability
Songyi Xue, Wei Xu, Lei Wang, et al.
ACS Central Science (2023) Vol. 9, Iss. 5, pp. 1046-1058
Open Access | Times Cited: 3
Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions
Aishi Dasgupta, Shon Gangai, Rishikesh Narayan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14411-14433
Closed Access | Times Cited: 3
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants
Emiel Vanhulle, Jordi Doijen, Joren Stroobants, et al.
Antiviral Research (2023) Vol. 213, pp. 105587-105587
Open Access | Times Cited: 2
Chemically modified antiviral peptides against SARS‐CoV‐2
Michael Quagliata, Anna Maria Papini, Paolo Rovero
Journal of Peptide Science (2023)
Open Access | Times Cited: 2
The Mechanism of Selective Recognition of Lipid Substrate by hDHHC20 Enzyme
Irina S. Panina, Nikolay A. Krylov, Anton O. Chugunov, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14791-14791
Open Access | Times Cited: 2
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants
Emiel Vanhulle, Jordi Doijen, Joren Stroobants, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top